Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly-rich RNA elements (PREs) are regulatory sequences found within the 3' untranslated regions (UTRs) of messenger RNAs (mRNAs) that consist of repetitive or enriched sequences of a single nucleotide, most commonly adenosine (A) or uridine (U) (Choi et al., 2020). These elements, which include AU-rich elements (AREs) and GU-rich elements (GREs), serve as critical binding sites for various RNA-binding proteins (RBPs) that control the stability, localization, and translation efficiency of the host mRNA (Garcia-Maurino et al., 2017). In many diseases, such as cancer and chronic inflammation, the dysregulation of PRE-mediated mRNA decay leads to the over-stabilization and overexpression of potent oncogenes and pro-inflammatory cytokines like TNF-alpha and MYC (Choi et al., 2020). Consequently, PREs have emerged as attractive therapeutic targets for small molecules and antisense oligonucleotides (ASOs) designed to either displace pathological RBPs or recruit nucleases to selectively degrade disease-associated transcripts (Disney et al., 2018). Recent advances in RNA-targeted drug discovery, including the development of Ribonuclease Targeting Chimeras (RIBOTACs), have demonstrated the feasibility of modulating gene expression by directly binding to these poly-rich motifs (Choi et al., 2020).
Small molecules or ASOs bind to the poly-rich sequences to displace RNA-binding proteins (RBPs), recruit nucleases for targeted degradation (e.g., via RIBOTACs), or modulate mRNA stability and translation efficiency by altering the transcript's half-life.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly-rich RNA elements (PREs).